Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Ability to receive intralesional injections

          4. Male or female, aged ≥ 18 years

          5. Histologically confirmed cutaneous squamous cell carcinoma, or basal cell carcinoma
             with accessible lesions (based on archival tissue or new tissue biopsy for
             histological confirmation)

          6. Life expectancy of at least 24 weeks at the time of screening

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          8. Must have measurable disease greater than 3 mm

          9. At least one injectable lesion

         10. Adequate organ function as defined below (Note: these screening laboratory tests must
             be obtained within two weeks prior to the baseline visit, Day 0):

             10.1. Hemoglobin (Hb) >10 g/dL 10.2. Absolute Neutrophil Count (ANC) >1,500 cells/mcL
             10.3. Platelet Count (PLT) >75,000/mcL 10.4. Prothrombin Time (PT) or International
             Normalized Ratio (INR) ≤1.5 times the institutional ULN unless patient is receiving
             anticoagulant therapy as long as PT or INR is within therapeutic range of the intended
             use of anticoagulants.

             10.5. Activated Partial Thromboplastin Time (aPTT) ≤1.5 times the institutional ULN
             unless patient is receiving anticoagulant therapy as long as aPTT is within
             therapeutic range of the intended use of anticoagulants.

             10.6. Serum Creatinine (SCr) ≤1.5 times the institutional ULN 10.7. Total Bilirubin
             ≤1.5 times the institutional ULN 10.8. Aspartate Aminotransferase (AST) ≤3 times the
             institutional ULN 10.9. Alanine Aminotransferase (ALT) ≤3 times the institutional ULN
             10.10. Lactate Dehydrogenase (LDH) ≤2 times the institutional ULN 10.11. Alkaline
             Phosphatase (ALP) ≤2.5 times the institutional ULN 10.12. Gamma GT (GGT) ≤2.5 times
             the institutional ULN

         11. Lymphocyte count ≥500,000 cells/mL

         12. For females of reproductive potential: must have a negative urine or serum pregnancy
             test result within 24 hours prior to receiving IFx-Hu2.0; must use highly effective
             contraception (e.g.,licensed hormonal or barrier methods) for at least one month prior
             to screening and agreement to use such a method during study participation and for an
             additional 26 weeks after the end of study treatment

         13. For males of reproductive potential: use of barrier method or other methods to ensure
             effective contraception with partner

        Exclusion Criteria:

          1. Concurrent participation in any other clinical trial

          2. Inability to consent for self

          3. Lesions on scalp with bone erosions must not be selected as injection sites for
             IFx-Hu2.0

          4. Life expectancy of fewer than 24 weeks at the time of screening

          5. Prior systemic anti-cancer treatment within three weeks from start of treatment (Day
             0)

          6. Treatment with any investigational product within the three weeks preceding injection

          7. Concurrent chemotherapy or biological therapy. Concurrent radiotherapy is allowed as
             long as it is not the same site as the injected lesion.

          8. Current treatment with systemic immunosuppressive corticosteroid (greater than 10 mg
             of daily prednisone) doses or other immunosuppressants such as those needed for solid
             organ transplants. Medications needed to treat conditions such as reactive airway
             disease are not excluded.

          9. Is pregnant, breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 26 weeks after the last dose of trial treatment

         10. Immunizations for encapsulated bacteria were not given for patients who have undergone
             a splenectomy

         11. Serious underlying medical or psychiatric conditions, active infections requiring the
             use of antimicrobial drugs, or active bleeding that would make the subject unsuitable
             or unable to participate in the study

         12. Active Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) or
             Hepatitis B/C. Patients with treated HIV/AIDS or Hepatitis B/C with no evidence of
             active infection may be enrolled

         13. History of organ allograft transplantation

         14. Presence of any uncontrolled and significant medical or psychiatric condition which
             would interfere with trial safety assessments